Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer

被引：0
|
作者：
Kim, Jin-Soo [1 ]
Han, Hye-Suk [1 ]
Im, Seock-Ah [1 ]
Oh, Do-Youn [1 ]
Han, Won-Shik [1 ]
Lee, Se-Hoon [1 ]
Kim, Dong-Wan [1 ]
Kim, Tae-You [1 ]
Noh, Dong-Young [1 ]
Bang, Yung-Jue [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [21] First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer
    Xie, Hui
    Li, Wei
    Yao, Yufeng
    Ni, Sujie
    Yi, Tongbo
    Cheng, Jinling
    Fang, Qi
    Zhang, Lei
    Zhou, Jun
    Wu, Xiaohong
    Wang, Chunbin
    Zhang, Yanan
    Qin, Jianwei
    Shao, Qing
    Zhao, Tao
    Huang, Xiaohong
    Xu, Lingyun
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer
    Acuña, LR
    Langhi, M
    Pérez, J
    Acuña, JR
    Machiavelli, M
    Lacava, J
    Vallejo, C
    Romero, A
    Fasce, H
    Ortiz, E
    Grasso, S
    Amato, S
    Rodríguez, R
    Barbieri, M
    Leone, B
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 74 - 81
  • [23] Weekly paclitaxel, doxorubicin, and carboplatin in the first-line treatment of patients with metastatic breast cancer
    Hainsworth, JD
    Burris, HA
    Greco, FA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 13 - 13
  • [24] Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer
    Chitapanarux, Imjai
    Kamnerdsupaphon, Pimkhuan
    Tharavichitkul, Ekasit
    Lorvidhaya, Vicharn
    Trakultivakorn, Hongsin
    Srisukho, Songpol
    Somwangprasert, Areewan
    Watcharachan, Kirati
    Sukthomya, Vimol
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 76 - 82
  • [25] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
    Yu, Y. F.
    Wang, Y.
    Fu, T. P.
    Chen, K.
    Liu, J. Q.
    Yao, H. R.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 337 - 348
  • [27] Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
    Y. F. Yu
    Y. Wang
    T. P. Fu
    K. Chen
    J. Q. Liu
    H. R. Yao
    Breast Cancer Research and Treatment, 2018, 168 : 337 - 348
  • [28] A randomised phase 2 study of 3 weekly cabazitaxel vs weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer
    Bahl, Amit
    Braybrooke, Jeremy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer.
    Unich, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Janicke, F.
    Muscholl, M.
    Pausehinger, M.
    Thomssen, C.
    Leide, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S185 - S186
12345